Stock Chart

BCAB

$1.74 -44.75%
Score: 38.8 SELL
Pro
Screener
Vol: 12.98x (vs SPY: 12.3x | vs QQQ: 12.0x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Aug 28, 2026
No qualifying chart pattern in the trailing 60 sessions — we only flag setups that pass our quality gate.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About BCAB - BioAtla, Inc. Common Stock

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Key Statistics

Market Cap $5M

More BCAB Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This BCAB stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track BCAB's price movements with trendlines, gamma walls, and key support/resistance levels.